Oncology – Page 19

KEYNOTE-991: Pembrolizumab Does Not Improve Outcomes in Metastatic Hormone-Sensitive Prostate Cancer—A Phase III Clinical Trial Analysis

By MedXY 08/08/2025

KEYNOTE-991 shows pembrolizumab does not improve progression-free or overall survival for mHSPC, and increases serious adverse events when added to enzalutamide and ADT.

Medical News news Oncology Radiology Specialties

CT Scans Linked to 5% of New U.S. Cancer Cases: Unpacking the Evidence and Clinical Implications

By MedXY 08/08/2025

A UCSF-led study estimates that CT scans may account for 5% of new cancer cases annually in the U.S., highlighting the need for careful imaging use and dose reduction strategies.

Clinical Updates news Oncology Specialties

LEAP-015: Evaluating Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy Alone in Advanced Gastroesophageal Adenocarcinoma

By MedXY 08/07/2025

The LEAP-015 phase III trial found that adding lenvatinib and pembrolizumab to chemotherapy marginally improved progression-free survival but not overall survival in advanced gastroesophageal adenocarcinoma, with increased toxicity.

news OB/GYN & Women's Health Oncology Specialties

Breast Nodules: How Close Are They to Breast Cancer?

By MedXY 08/07/2025

This article explores the relationship between breast nodules and breast cancer, addressing common concerns and offering actionable health insights.

news OB/GYN & Women's Health Oncology Specialties

Early Signs of Ovarian Cancer: Understanding the Three Common Areas of Itching and Common Misdiagnoses Among Women

By MedXY 08/07/2025

Ovarian cancer often presents subtle early symptoms like itching in the abdomen, genital area, and legs, which are frequently misinterpreted. Recognizing these signs is crucial for timely diagnosis and treatment.

Clinical Updates General Surgery news Oncology Radiology Specialties

Surgery or Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF Trials

By MedXY 08/07/2025

The SURF trials found no significant difference in survival or recurrence-free outcomes between surgery and radiofrequency ablation for small hepatocellular carcinoma, supporting RFA as a less invasive, equally effective option.

Clinical Updates news OB/GYN & Women's Health Oncology Specialties

First-Line Camizestrant for ESR1-Mutated Advanced Breast Cancer: Redefining Endocrine Therapy Resistance

By MedXY 08/07/2025

Next-generation SERD camizestrant significantly prolongs progression-free survival over aromatase inhibitors or fulvestrant in ESR1-mutated, ER-positive, HER2-negative advanced breast cancer, with favorable safety and quality-of-life profiles.

Clinical Updates news OB/GYN & Women's Health Oncology Specialties

Vepdegestrant: A Next-Generation Oral PROTAC ER Degrader for Advanced ER+/HER2– Breast Cancer—VERITAC-2 Results and Clinical Implications

By MedXY 08/07/2025

Vepdegestrant, an oral PROTAC estrogen receptor degrader, significantly prolongs progression-free survival compared to fulvestrant in ESR1-mutant advanced breast cancer, but not in the overall ER+/HER2– population.

Clinical Updates news Oncology Radiology Specialties

Reduced Elective Radiotherapy Dose in Head and Neck Cancer: New Evidence from the UPGRADE-RT Trial

By MedXY 08/07/2025

The UPGRADE-RT multicenter trial confirms that lowering elective neck irradiation dose in definitive radiotherapy for head and neck cancer maintains disease control and improves quality of life, reducing toxicity without increasing recurrence risk.

Clinical Updates news Oncology Specialties

Timing Matters: Sequential Pembrolizumab Plus Chemoradiation Outperforms Concurrent Approach in Locally Advanced Head and Neck Cancer

By MedXY 08/07/2025

A Phase II trial finds sequential pembrolizumab after chemoradiation achieves superior locoregional control compared to concurrent administration in locally advanced head and neck squamous cell carcinoma.

Clinical Updates General Surgery news Oncology Specialties

Long-Term Outcomes of Transoral Surgery with Risk-Adapted Adjuvant Therapy in HPV-Positive Oropharyngeal Cancer: Results from the E3311 Trial

By MedXY 08/07/2025

The E3311 phase II trial shows excellent long-term survival with deintensified postoperative management after transoral surgery in HPV-associated oropharyngeal cancer, with most patients spared from high-dose radiation and chemotherapy.

Clinical Updates news Oncology Specialties

Personalizing Oxaliplatin Dosing: Reducing Neurotoxicity in Stage III Colon Cancer—Insights from the LEANOX Trial

By MedXY 08/07/2025

LBM-based oxaliplatin dosing significantly reduces peripheral neurotoxicity without compromising survival outcomes in adjuvant treatment for stage III colon cancer.

Clinical Updates General Surgery news Oncology Specialties

Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF-RCT and SURF-Cohort Trials

By MedXY 08/07/2025

The SURF trials found no significant difference in survival or recurrence between surgery and radiofrequency ablation for small hepatocellular carcinoma, supporting both as valid first-line options.

Clinical Updates Oncology Specialties Urology

PARP inhibitors shine: How the TALAPRO-2 trial is changing the landscape of prostate cancer with precision medicine

By Dr.Paul 08/07/2025

Treatment for advanced prostate cancer has advanced significantly in the past decade, but metastatic castration-resistant…

Clinical Updates Oncology Specialties

No Added Survival Benefit from Adjuvant Chemotherapy in Older Women with Genomically High-Risk Hormone Receptor-Positive Breast Cancer: Results from the ASTER 70s Trial

By MedXY 08/07/2025

The ASTER 70s trial found that adding chemotherapy to hormonotherapy did not improve survival but increased toxicity in women aged 70+ with high-risk ER+/HER2- breast cancer.

Clinical Updates news Oncology Specialties

Revolutionizing Cancer Therapy: Synergistic Action of Two Natural Bacteria in Complete Tumor Eradication

By MedXY 08/06/2025

A novel bacteria-based therapy using two natural strains demonstrates complete tumor clearance in immunocompromised models, offering hope for cancer patients unsuitable for current immunotherapies.

Clinical Updates news Oncology Specialties

Curcumin Shows Promise in Targeting Colorectal Cancer Stem-like Cells: Mechanistic Insights and Clinical Implications

By MedXY 08/06/2025

Curcumin, derived from turmeric, targets colorectal cancer stem-like cells, inhibits tumor growth, and promotes differentiation, offering new opportunities for cancer prevention strategies.

Clinical Updates Family Medicine & Nutrition news Oncology Specialties

Vitamin C as a Cardioprotective Agent Against Doxorubicin-Induced Cardiotoxicity

By MedXY 08/06/2025

This review explores vitamin C's potential to protect the heart from doxorubicin-induced damage by reducing oxidative stress and preserving cardiac function, highlighting the need for further clinical studies.

Clinical Updates news Oncology Specialties

Decoding Oncology Trial Endpoints: OS, DFS, PFS, ORR, CR, PR, SD, PD, and DCR Explained

By MedXY 08/06/2025

This article demystifies key clinical trial efficacy endpoints in oncology, including OS, DFS, PFS, ORR, CR, PR, SD, PD, and DCR, providing clinicians with a practical guide to their definitions, roles, and interpretation.

Clinical Updates news Oncology Specialties

Beyond Negative: Quantitative Fecal Hemoglobin Levels Refine Colorectal Cancer Risk Stratification in FIT-based Screening

By MedXY 08/06/2025

New meta-analysis reveals a strong dose-response relationship between fecal hemoglobin concentration and colorectal neoplasia risk, even among FIT-negative individuals, supporting personalized screening intervals.